Month: March 2025

BNC First Day® Program Revenues Increased 21% YOY to $222 Million Total Revenue Growth of 2% and Gross Comparable Store Sales Growth of 7% Net Income Improves by $17 Million to $7 Million Adjusted EBITDA Improves by $6 Million to $27 Million BASKING RIDGE, N.J., March 10, 2025 (GLOBE NEWSWIRE) — Barnes & Noble Education, Inc. (NYSE: BNED), (“Barnes & Noble Education,” “BNED,” the “Company,” “we,” “us,” “our”), a leading solutions provider for the education industry, today reported sales and earnings for the third quarter ended on January 25, 2025 (“Q3”). The following figures are GAAP results from continuing operations on a consolidated basis, unless noted otherwise. Note that Adjusted EBITDA is a non-GAAP calculation. Full quarterly financial tables and a reconciliation of non-GAAP measures to the most applicable GAAP...

Company to Host Conference Call and Webcast at 8:30 AM ET on March 11, 2025 PALM BEACH GARDENS, Fla., March 10, 2025 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (“we,” “our,” the “Company” or “GECC”) (NASDAQ: GECC), a business development company, today announced its financial results for the fourth quarter and full year ended December 31, 2024.       Fourth Quarter and Other Recent HighlightsIn December 2024, the GECC raised $13.2 million of equity at Net Asset Value from Summit Grove Partners, LLC (“SGP”), supported by a $3.3 million investment by Great Elm Group, Inc. (“GEG”) in SGP. Net investment income (“NII”) for the quarter ended December 31, 2024 was $2.1 million, or $0.20 per share, as compared to $4.1 million, or $0.39 per share, for the quarter ended September 30, 2024.Timing of distributions from CLO Formation...

Fourth Quarter ResultsTotal revenues of $45.0 million, a 28% year-over-year improvement Net income of $3.5 million and earnings per diluted share of $1.32, an improvement to the prior year period after adjusting for the non-cash benefit of legal settlement from one year ago Adjusted EBITDA of $8.2 million, compared to $2.5 million in the fourth quarter of 2023   $25.9 million in cash and $8.1 million in debt as of December 31, 2024Full Year ResultsTotal revenues of $162.6 million, a 14% improvement over 2023 Gross margin improved to 40% from 37% in 2023; Adjusted gross margin improved to 41% from 39% in 2023   Net income of $6.6 million and earnings per diluted share of $2.55, an improvement to the net loss of $(3.2) million and loss per share of $(1.27) in 2023 Adjusted EBITDA of $22.3 million, compared to $11.9 million in 2023 Cash...

Grows Fully Diluted Book Value by 7.2% in 2024, Marking Fifth Consecutive Year of Book Value Growth; Increases Transparency with New Reporting Segments GRAND CAYMAN, Cayman Islands, March 10, 2025 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2024. Effective December 31, 2024, the Company restructured its reportable segments to better align with its multi-pillar strategy. Moving forward, the Company will report financial results under two segments, Open Market and Innovations. Additionally, prior-period results have been revised to ensure consistency with the new reporting structure. Fourth Quarter 2024 Highlights (all comparisons are to fourth quarter 2023 unless noted otherwise):Gross premiums...

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29% quarter-over-quarter – – UDENYCA divestiture on track with Special Meeting of Shareholders taking place March 11, 2025; transaction expected to close late in the first quarter or early in the second quarter of 2025 – – Post divestiture expected cash of approximately $250 million, with cash runway exceeding two years; Company headcount to be reduced by approximately 30% – – Catalyst-driven 2025/2026 with multiple clinical data readouts across the Company’s innovative oncology pipeline – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq:...

— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025 — $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026 BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) — OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. “I am extremely...

SHAKOPEE, Minn., March 10, 2025 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2024. ($ in thousands, except per share data and percentages)         Three Months Ended December 31,   Twelve months ended December 31,  2024   2023   Change   2024   2023   ChangeNet revenues $11,978     $12,527     -4.4 %   $61,562     $61,437     0.2 %Net income(1) -$1,245     $1,364     -191.3 %   $2,113     $10,563     -80.0 %Adjusted EBITDA(2) $1,335     $2,051     -34.9 %   $10,234     $10,446     -2.0 %                       Basic EPS(1) -$0.25     $0.28     -189.3 %   $0.42     $2.15     -80.5 %Diluted EPS(1) -$0.25     $0.27     -192.6 %   $0.42     $2.13     -80.3 %                                   (1) ...

BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the fourth quarter and full year ended December 31, 2024. Highlights:Q4 revenue increased 18% year over year. Full year revenue increased 12% to $90.4 million and EPS improved 19% year over year. Positive operating and free cash flow for both Q4 and the full year.“As planned, we have delivered positive free cash flow for both Q4 and the full year,” said Jirka Rysavy, Gaia’s Chairman. “Our price increase during second part of the year has already shown positive revenue impact with 18% revenue growth in the quarter. The price increase combined with investments in content, AI and community, shall further improve Gaia’s position.” “2024 was a year of strengthening our member base,...

— CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 — — Advancing four clinical programs for hematologic malignancies and autoimmune diseases — — $249.4 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2026 — BERKELEY, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2024 and reviewed recent pipeline progress. “Caribou is planning for two clinical data disclosures in the first half of 2025 as we advance the development of our off-the-shelf CAR-T cell therapies in oncology and autoimmune diseases,” said...

Achieved record fiscal first quarter revenue driven by higher price and volume in the Marketing & Distribution segment OXNARD, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today reported its financial results for the fiscal first quarter ended January 31, 2025. Fiscal First Quarter 2025 Financial Overview:Total revenue increased 29% to $334.2 million compared to the same period last year Net income of $3.9 million, or $0.05 per diluted share, compared to $0.0 million, or $0.00 per diluted share, for the same period last year Adjusted net income of $7.1 million, or $0.10 per diluted share, compared to $6.7 million, or $0.09 per diluted share, for the same period last year Adjusted EBITDA...